Essential3: An Innovative Multi-Study Phase 3 Program to Evaluate the Efficacy and Safety of Ulixacaltamide
Objective: An innovative, multi-study Phase 3 program to definitively assess safety and efficacy of ulixacaltamide in essential tremor (ET). Background: Phase 2 studies of ulixacaltamide,…A case of malignant Deep Brain Stimulation Withdrawal Syndrome treated with Opicapone
Objective: We present a case of a patient with Parkinson's disease who developed "malignant Deep Brain Stimulation (DBS) Withdrawal Syndrome" following the removal of the…Impact of IPX203 on Parkinson’s patients’ motor states upon awakening: analysis of patient diary data
Objective: To evaluate “On” upon awakening in Parkinson’s disease patients taking IPX203 in the RISE-PD phase 3 clinical trial. Background: IPX203 is a novel extended-release,…Suvecaltamide Metabolites Are CaV3 Modulators and Contribute to Pharmacological Effect
Objective: To determine the potency-concentration relationships and combined pharmacological effects for suvecaltamide and its 2 active metabolites (JZZ05000034=M01, JZZ05000035=M02; total active moiety [TAM]). Background: T-type…Multicentric Randomized Control Trial of Buspirone in Levodopa-Induced Dyskinesias
Objective: To investigate the efficacy of buspirone on levodopa induced dyskinesias (LID) in Parkinson disease (PD) patients Background: LID could be partially mediated by the…Contribution to Efficacy by Active Metabolites of Suvecaltamide in a Preclinical Rat Model of Essential Tremor
Objective: Present the pharmacokinetic/pharmacodynamic (PK/PD) relationship and contribution to anti-tremor efficacy for suvecaltamide and its active metabolites (JZZ05000034=M01, JZZ05000035=M02) in a harmaline-induced rat model of…Effect of the 5-HT2A/2C inverse agonist nelotanserin on dyskinesia in the MPTP-lesioned marmoset
Objective: To determine the effect of the serotonin 2A/2C (5-HT2A/2C) receptor inverse agonist nelotanserin on dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned marmoset. Background: Nelotanserin is a…What change to expect in duration of benefit per dose when switching from IR CD-LD to IPX203 (ER CD-LD)
Objective: To investigate if duration of benefit (“Good On” time) per dose during immediate-release (IR) carbidopa-levodopa (CD-LD) treatment predicts response to IPX203 conversion. Background: Levodopa’s…Effect of variants in COMT and UGT1A genes on clinical response in patients with Parkinson’s disease treated with opicapone
Objective: To identify genetic variants associated with different clinical responses in patients with Parkinson’s disease(PD) treated with opicapone. Background: Opicapone is a catechol‐O‐methyltransferase(COMT) inhibitor used…24(S)-Hydroxycholesterol and cognition in Huntington’s disease: results from two large patient cohorts (TRACK-HD and ENROLL-HD)
Objective: To investigate correlations between plasma levels of 24(S)-Hydroxycholesterol (24[S]-HC) and cognitive performance in participants with Huntington’s disease (HD) using data from ENROLL-HD. Background: HD…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 34
- Next Page »